

AMENDMENTS TO THE SPECIFICATION

Please enter on page 1 the following new paragraph [0001] before the FIELD OF THE INVENTION:

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a Continuation of co-pending U.S. Patent Application 10/194,868, filed on 11 July 2002, and whose entire contents are hereby incorporated by reference.

Please amend the following text on Page 2, line 14:

The Mechano-receptors are tension sensors activated in response to the contraction and extension of the stomach and intestines and are the primary receptors associated with [[bowl]] bowel occlusion-related emesis.

Please amend the following text on Page 6, lines 5 and 8:

For example, and not intended as a limitation, an [[ant]] anti-emetic composition of the present invention having 1% lorazepam would have 1 gram of lorazepam per 100 grams of the total composition (i.e., 1 gram of lorazepam plus 99 grams of other ingredients). In those cases where the total amount of active ([[ant]] anti-emetic) ingredient(s) do not total 100%, it is presumed that the difference totaling 100% is made up of pharmaceutically acceptable excipients as defined herein.

Please amend the following text on Page 6, line 21:

Unit: "Unit" or "unit dose" as used herein refers to a single [[doe]] dose. The unit may be a pill such as a caplet, capsule, gelcap or tablet.

Please amend the following text on Page 12, line 4:

Compound	Amount Per 100 260 mg Capsules
Lorazepam USP	25 mg
Promethazine USP	1250 mg
Diphenhydramine	1250 mg
Metoclopramide USP	1000 mg
Lactose [[monhydrate]] monohydrate USP	1000 mg

Please amend the following text within the ABSTRACT OF THE INVENTION on Page 16:

Broad-spectrum anti-emetic pharmaceutical compositions are disclosed. The [[discloses]] broad-spectrum [[ant]] anti-emetics disclosed herein comprise selected neuroreceptor antagonists specifically formulated to treat and prevent to most common forms of emesis. In one embodiment the [[ant]] anti-emetic compositions include lorazepam, diphenhydramine, promethazine, and metoclopramide. The pharmaceutical compositions include, but are not limited to oral and parenteral forms and may include one or more pharmaceutically acceptable excipient.